Detail akcie Emergent Bio online

Business Summary: Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Emergent Biosolutions Inc revenues increased 8% to $390.4M. Net loss totaled $173.4M vs. income of $56M. Revenues reflect MCM Products segment increase of 25% to $269.8M, U.S.Government segment increase of 67% to $227.9M. Net loss reflects Impairment of long-lived assets increase from $0K to $191.3M (expense), Other (expense) income, net decrease of 79% to $13.9M (income).